Fig. 5: Effects of HSP90 inhibition on mutant EGFR signalling. | British Journal of Cancer

Fig. 5: Effects of HSP90 inhibition on mutant EGFR signalling.

From: TAS-116 inhibits oncogenic KIT signalling on the Golgi in both imatinib-naïve and imatinib-resistant gastrointestinal stromal tumours

Fig. 5

a EGFR gene mutation and effects of gefitinib, TAS-116 and 17-AAG in gefitinib-naïve and gefitinib-resistant lung cancer cell lines. b Cell proliferation was determined by WST-8 assays at 72 h after incubation with TAS-116. Each value is represented as the mean ± SD. c Western blot analysis of HSP70, pEGFR/EGFR, pAKT/AKT and pERK/ERK in NCI-H1975 cell lysates at 24 h after gefitinib, TAS-116 or 17-AAG treatment was performed. d NCI-H1975 cells were treated with 2 μM TAS-116 or 0.1 μM 17-AAG for 24 h. Cells were stained with anti-EGFR (green), and anti-TfR antibodies (endosome marker, red). Bars, 20 μm.

Back to article page